BioSurface Technology
This article was originally published in The Gray Sheet
Executive Summary
Temporarily halts clinical trials of its Acticel wound dressing for treatment of burn patient donor site wounds after finding an "equivocal" reduction in average healing time for the indication. Pilot studies had shown a "clinically significant" time reduction, according to the company. BioSurface is conducting an "intensive" analysis of both data and study design to determine how best to proceed. Acticel trials in five other indications, such as deep partial thickness burns and pressure ulcers ("The Gray Sheet" Jan. 11, p. 16), will continue.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.